Wealthquest Corp Boosts Stake in Pfizer Inc. (NYSE:PFE)

Wealthquest Corp lifted its holdings in Pfizer Inc. (NYSE:PFE) by 8.1% during the second quarter, Holdings Channel reports. The institutional investor owned 22,012 shares of the biopharmaceutical company’s stock after purchasing an additional 1,653 shares during the quarter. Wealthquest Corp’s holdings in Pfizer were worth $953,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of PFE. Evolution Wealth Advisors LLC purchased a new stake in Pfizer during the second quarter worth $34,000. IMA Wealth Inc. boosted its position in Pfizer by 144.5% during the second quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 477 shares in the last quarter. Winch Advisory Services LLC boosted its position in Pfizer by 69.6% during the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 336 shares in the last quarter. Ruggie Capital Group purchased a new stake in Pfizer during the fourth quarter worth $44,000. Finally, Karp Capital Management Corp purchased a new stake in Pfizer during the fourth quarter worth $53,000. Hedge funds and other institutional investors own 71.82% of the company’s stock.

PFE has been the topic of a number of research analyst reports. Barclays reiterated a “hold” rating and set a $41.00 target price on shares of Pfizer in a research report on Thursday, May 9th. Bank of America downgraded Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 30th. Credit Suisse Group began coverage on Pfizer in a report on Monday, July 15th. They issued a “hold” rating and a $47.00 price target for the company. Goldman Sachs Group reissued a “buy” rating and issued a $49.00 price target on shares of Pfizer in a report on Monday, June 17th. Finally, JPMorgan Chase & Co. set a $46.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Monday, July 29th. Fifteen research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Pfizer presently has an average rating of “Hold” and an average price target of $46.44.

In related news, EVP Frank A. Damelio sold 153,184 shares of the company’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total value of $6,753,882.56. Following the completion of the transaction, the executive vice president now directly owns 489,647 shares in the company, valued at $21,588,536.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Pfizer Inc bought 50,000 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was acquired at an average price of $17.00 per share, with a total value of $850,000.00. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

Shares of NYSE PFE traded down $0.25 during trading on Friday, reaching $38.00. The company had a trading volume of 27,652,919 shares, compared to its average volume of 28,194,710. Pfizer Inc. has a twelve month low of $37.68 and a twelve month high of $46.47. The stock has a market capitalization of $212.67 billion, a PE ratio of 12.67, a PEG ratio of 3.05 and a beta of 0.63. The business’s 50-day simple moving average is $42.85. The company has a quick ratio of 1.27, a current ratio of 1.54 and a debt-to-equity ratio of 0.60.

Pfizer (NYSE:PFE) last released its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.05. The firm had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 27.57% and a net margin of 23.58%. The business’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.77 earnings per share. Equities research analysts expect that Pfizer Inc. will post 2.8 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be paid a $0.36 dividend. The ex-dividend date is Thursday, August 1st. This represents a $1.44 annualized dividend and a yield of 3.79%. Pfizer’s payout ratio is currently 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: How Do Mutual Funds Work?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.